Acumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022
August 08 2022 - 4:15PM
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage
biopharmaceutical company focused on the development of novel
targeted therapeutics for Alzheimer’s disease (AD), today announced
that the Company will report its financial results for the second
quarter 2022 on Monday, August 15, 2022. The company will host a
conference call and live audio webcast at 4:30 p.m. ET to provide a
business and financial update.
To participate in the live conference call, please register
using this link. After registration, you will be informed of the
dial-in numbers including PIN. Please register at least one day in
advance.
The audio will be available via this link.
An archived version of the webcast will be available for at
least 30 days in the Investors section of the Company's website at
www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.Acumen,
headquartered in Charlottesville, VA, with clinical operations
based in Carmel, IN, is a clinical stage biopharmaceutical company
developing a novel disease-modifying approach to treat Alzheimer’s
disease. Acumen’s scientific founders pioneered research on AβOs,
which a growing body of evidence indicates are primary triggers of
Alzheimer’s disease pathology. Acumen is currently focused on
advancing its investigational immunotherapy drug, ACU193, a
humanized monoclonal antibody that selectively targets toxic AβOs
in INTERCEPT-AD, a Phase I clinical trial involving early
Alzheimer’s disease patients. For more information, visit
www.acumenpharm.com.
Contacts:
Media:AcumenPR@westwicke.com
Investors:investors@acumenpharm.com
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Jul 2023 to Jul 2024